


PCIPA 2004/001918






- 7 - 08 FEBRUARY 2006 03-02.06



I

wherein,

5 R is  $\text{NH}-(\text{A})_n-\text{CH}_2\text{OH}$ ;



A is D or L amino acid and  $n=1-10$ ,

$R_1$  and  $R_2$  are each independently, hydrogen, alkyl of 1-6 carbons atoms, hydroxyalkyl of 1-6 carbon atoms, or  $\text{CO}_2\text{R}_8$ ,

PCIMA 2004/001918

03 FEBRUARY 2006 03-02.06

- 8 -

R<sub>3</sub> is Ar, wherein Ar is aromatic or heteroaromatic;

R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> are each independently alkyl of 1-6 carbon atoms or hydroxyalkyl of 1-6 carbon atoms;

R<sub>7</sub> is alkyl of 1-10 carbon atoms;

5 R<sub>8</sub> is alkyl of 1-6 carbon atoms; and

R<sub>9</sub> is cycloalkoxyalkyl of 4-10 carbon atoms;



wherein R and said compound of formula I are linked through a carbamate ester linkage.

10 In one embodiment, amino acids and/or small peptides derivatives of the octapeptide HSKRRLLIF are conjugated with rapamycin (formula 5). The regioselective synthesis of derivatives of rapamycin 5 at the 42 position, is achieved by conjugating the amino end of the amino acids and/or active peptides with 42-O-(4-Nitrophenoxycarbonyl)  
15 rapamycin (6). Compounds of general formula 7 (Scheme 1) are thereby obtained.

06 SEPTEMBER 2005 06.09.05

- 9 -

Scheme 1



5       !

      The peptides conjugated to rapamycin preferably  
 comprise amino acids from the C-terminal of the  
 octapeptide HSKRRLIF. The amino acids at the N-terminal  
 may differ from that of the octapeptide. Single amino  
 10 acids may also be used. Examples of compounds obtained by  
 the combination of 42-O-(4-Nitrophenoxycarbonyl)  
 rapamycin and amino acids and/or peptides are given below  
 (compounds 7a to 7v).

AMENDED SHEET

- 9a -

The peptides used to derive 42-O-(4-Nitrophenoxy carbonyl) rapamycin can be synthesized from amino alcohols. The first amino acid is kept as Phe-OH (or 2-amino-3-phenyl-propanol) and performing chain  
5 elongation with Fmoc chemistry in solution phase (**Scheme 2**) using DCC/HOBt as the coupling reagents.

**AMENDED SHEET**















PCNCA 2004/001918

- 12 -

03 FEBRUARY 2006 03-02.06

alcohols. Compounds 7j to 7v are examples of such amino alcohols-rapamycin conjugates (Sheet 1).

Sheet 1

7a NH-L-Ile-D-Phe-CH<sub>2</sub>OH7c NH-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH7e NH-L-Ala-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH7g NH-N-Ile(Trityl)-D-His-L-Ala-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH7i NH-L-His-L-Ala-L-Lys-L-Arg-L-Arg-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH7b NH-L-Ile-S-Phe-CH<sub>2</sub>OH7d NH-D-Leu-L-Ile-S-Phe-CH<sub>2</sub>OH7f NH-D-Ala-D-Leu-L-Ile-S-Phe-CH<sub>2</sub>OH7h NH-N-Ile(Trityl)-D-His-L-Ala-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH

DOCSOTT: 452732A1

AMENDED SHEET


PCT/CA 2004/001918

03 FEBRUARY 2006 03-02.06



The conjugations of rapamycin with amino alcohols or peptides comprising an amino alcohol at the "C" terminal of the peptide provides increased hydrophilic character to the compound by virtue of the presence of the free hydroxyl group.

Other rapamycin conjugates (7w, 7x, 7y) exhibiting increase hydrophilicity are shown in sheet 2 below.

Sheet 2



7



DOCSOTT: 452732\1

AMENDED SHEET


PCT/CA 2004/001918

- 48 -

03 FEBRUARY 2006 03-02.06

I/WE CLAIM:






1. A compound of the formula



I

wherein,

R is  $\text{NH}-(\text{A})_n-\text{CH}_2\text{OH}$ ; or



wherein R as defined above comprises an amino acid; an amino alcohol or a peptide;


**PCDA 2004/001918****03 FEBRUARY 2006 03-02.06**

A is D or L amino acid and  $n=1-10$ ,  
 $R_1$  and  $R_2$  are each independently, hydrogen, alkyl of 1-6  
carbons atoms, hydroxyalkyl of 1-6 carbon atoms, or  $CO_2R_8$ ,  
 $R_3$  is Ar, wherein Ar is aromatic or heteroaromatic;  
 $R_4$ ,  $R_5$  and  $R_6$  are each independently alkyl of 1-6 carbon  
atoms or hydroxyalkyl of 1-6 carbon atoms;  
 $R_7$  is alkyl of 1-10 carbon atoms;  
 $R_8$  is alkyl of 1-6 carbon atoms; and  
 $R_9$  is cycloalkoxyalkyl of 4-10 carbon atoms;  
wherein R and said compound of formula I are linked  
through a carbamate ester linkage.



2. The compound as claimed in claim 1 wherein R is selected from:

Sheet 1



7a NH-L-Ile-D-Phe-CH<sub>2</sub>OH

7c NH-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH

7e NH-L-Ala-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH

7g NH-N-Im(Trityl)-D-His-L-Ala-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH













7i NH-L-His-L-Ala-L-Lys-L-Arg-L-Arg-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH

7d NH-L-Ile-S-Phe-CH<sub>2</sub>OH

7f NH-D-Leu-L-Ile-S-Phe-CH<sub>2</sub>OH

7h NH-D-Ala-D-Leu-L-Ile-S-Phe-CH<sub>2</sub>OH

7b NH-N-Im(Trityl)-D-His-L-Ala-L-Leu-L-Ile-D-Phe-CH<sub>2</sub>OH



3. A pharmaceutical composition comprising the compound as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically

- 51 -

PCT/CA 2004/001918

06 FEBRUARY 2006 06-02.06

acceptable carrier for use in treating cell proliferation disorders.

4. A method for treating a cell proliferation disorder comprising administering the pharmaceutical composition as claimed in claim 3 to a patient in need thereof in an amount sufficient to reduce cell proliferation.

5. The method as claimed in claim 4 wherein said cell proliferation disorder is selected from cancer, hyperplasia, psoriasis and hyperproliferative vascular disease.

6. The method as claimed in claim 5 wherein said hyperproliferative vascular disease is restenosis.

7. The method as claimed in claim 5 or 6 wherein said composition is released from a carrier, said carrier being implanted at a desired location within said patient.

8. The method as claimed in claim 7 wherein said carrier is implanted using a vascular guiding means.

9. The method as claimed in claim 8 wherein said vascular guiding means is a catheter.

10. A stent coated with the compound of claim 1 or 2 or the composition of claim 3.

11. The stent as claimed in claim 10 wherein said compound or composition is comprised within a coating composition.

12. The stent as claimed in claim 10 or 11 for treating a hyperproliferative vascular disease.

AMENDED SHEET

PCDA 2004/001918

03 FEBRUARY 2006 03-02.06

13. The stent as claimed in claim 12 wherein said hyperproliferative vascular disease is restenosis.

14. A pharmaceutical composition comprising the compound as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for use as an immunosuppressant.

15. A method for treating an immunological condition comprising administering the pharmaceutical composition as claimed in claim 14 to a patient in need thereof in an amount sufficient to suppress the immune system.

16. The method as claimed in claim 15 wherein said immunological disorder is selected from autoimmune disease and host-graft disease.

17. A process for the preparation of the compound of claim 1 or 2 comprising reacting 42-O-(4-Nitrophenoxy carbonyl)rapamycin and an amino acid or a peptide or an amino alcohol under basic conditions.

18. The process as claimed in claim 17 wherein said base is pyridine.

AMENDED SHEET

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**